Cargando…
抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的研究进展
Lung cancer has the highest incidence rate and mortality in China, even in the world, and non-small cell lung cancer (NSCLC) accounts for about 85%. The growth and metastasis of tumor depend on the generation of blood vessels, and anti-angiogenic therapy is playing an increasingly important role, ho...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143969/ https://www.ncbi.nlm.nih.gov/pubmed/33819970 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.05 |